Compare XAIR & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XAIR | IRIX |
|---|---|---|
| Founded | 2011 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 15.0M |
| IPO Year | 2015 | 1996 |
| Metric | XAIR | IRIX |
|---|---|---|
| Price | $2.66 | $0.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 120.7K | 44.3K |
| Earning Date | 06-16-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | N/A | ★ N/A |
| Revenue | $7,679,000.00 | ★ $41,593,000.00 |
| Revenue This Year | $122.00 | $3.07 |
| Revenue Next Year | $58.15 | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.61 |
| 52 Week High | $8.19 | $1.65 |
| Indicator | XAIR | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 35.05 |
| Support Level | $0.41 | $0.61 |
| Resistance Level | $2.66 | $0.98 |
| Average True Range (ATR) | 0.20 | 0.03 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 29.43 | 27.74 |
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
IRIDEX Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures used to treat sight-threatening eye conditions, including glaucoma and retinal diseases. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.